324 related articles for article (PubMed ID: 15827162)
1. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
Gudgeon NH; Taylor GS; Long HM; Haigh TA; Rickinson AB
J Virol; 2005 May; 79(9):5477-88. PubMed ID: 15827162
[TBL] [Abstract][Full Text] [Related]
2. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
[TBL] [Abstract][Full Text] [Related]
4. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Konttinen YT; Bluestein HG; Zvaifler NJ
J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
[TBL] [Abstract][Full Text] [Related]
7. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients.
Ruibal-Ares B; Belmonte L; Baré P; Scolnik M; Palacios MF; Bayo-Hanza C; Galmarini CM; Mendez G; de Bracco MM
J Hum Virol; 2001; 4(4):200-13. PubMed ID: 11694848
[TBL] [Abstract][Full Text] [Related]
8. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.
Vogl BA; Fagin U; Nerbas L; Schlenke P; Lamprecht P; Jabs WJ
J Med Virol; 2012 Jan; 84(1):119-31. PubMed ID: 22095540
[TBL] [Abstract][Full Text] [Related]
10. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
11. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
12. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
13. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
[TBL] [Abstract][Full Text] [Related]
14. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
Long HM; Haigh TA; Gudgeon NH; Leen AM; Tsang CW; Brooks J; Landais E; Houssaint E; Lee SP; Rickinson AB; Taylor GS
J Virol; 2005 Apr; 79(8):4896-907. PubMed ID: 15795275
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV)-induced long-term proliferation of CD4+ lymphocytes leading to T lymphoblastoid cell lines carrying EBV.
Guan M; Romano G; Henderson EE
Anticancer Res; 1999; 19(4B):3007-17. PubMed ID: 10652585
[TBL] [Abstract][Full Text] [Related]
17. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
19. [Application of Epstein-Barr virus-transformed B lymphoblastic cells in identification of CTL epitopes specific for Hantaan virus].
Wang ML; Zhang QH; Wang JP; Li YM; Ma Y; Jin BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jan; 25(1):20-2. PubMed ID: 19126382
[TBL] [Abstract][Full Text] [Related]
20. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
